Deletion of A44L, A46R and C12L Vaccinia Virus Genes from the MVA Genome Improved the Vector Immunogenicity by Modifying the Innate Immune Response Generating Enhanced and Optimized Specific T-Cell Responses.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 27223301)

Published in Viruses on May 23, 2016

Authors

María Pía Holgado1, Juliana Falivene2, Cynthia Maeto3, Micaela Amigo4, María Fernanda Pascutti5, María Belén Vecchione6,7, Andrea Bruttomesso8, Gabriela Calamante9, María Paula Del Médico-Zajac10, María Magdalena Gherardi11

Author Affiliations

1: Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Universidad de Buenos Aires-CONICET, Facultad de Medicina, Ciudad de Buenos Aires 1121, Argentina. piaholgado@gmail.com.
2: Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Universidad de Buenos Aires-CONICET, Facultad de Medicina, Ciudad de Buenos Aires 1121, Argentina. juliana.falivene@gmail.com.
3: Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Universidad de Buenos Aires-CONICET, Facultad de Medicina, Ciudad de Buenos Aires 1121, Argentina. cynthiamayumi85@gmail.com.
4: Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Universidad de Buenos Aires-CONICET, Facultad de Medicina, Ciudad de Buenos Aires 1121, Argentina. mfernandezamigo.19@gmail.com.
5: Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Universidad de Buenos Aires-CONICET, Facultad de Medicina, Ciudad de Buenos Aires 1121, Argentina. fpascutti@yahoo.com.ar.
6: Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Universidad de Buenos Aires-CONICET, Facultad de Medicina, Ciudad de Buenos Aires 1121, Argentina. mb_vecchione@hotmail.com.
7: Unidad de Microanálisis y Métodos Físicos Aplicados a Química Orgánica (UMYMFOR), Departamento de Química Orgánica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Buenos Aires 1428, Argentina. mb_vecchione@hotmail.com.
8: Unidad de Microanálisis y Métodos Físicos Aplicados a Química Orgánica (UMYMFOR), Departamento de Química Orgánica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Buenos Aires 1428, Argentina. andrea.bruttomesso@gmail.com.
9: Instituto de Biotecnología, CICVyA-INTA Castelar, Buenos Aires 1686, Argentina. calamante.gabriela@inta.gob.ar.
10: Instituto de Biotecnología, CICVyA-INTA Castelar, Buenos Aires 1686, Argentina. delmedicozajac.maria@inta.gob.ar.
11: Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Universidad de Buenos Aires-CONICET, Facultad de Medicina, Ciudad de Buenos Aires 1121, Argentina. mmgherardi@gmail.com.

Articles cited by this

NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol (1998) 21.48

Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods (2003) 11.81

Innate immunity to virus infection. Immunol Rev (2009) 7.04

Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat Med (2009) 5.54

Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors. Immunity (2006) 5.36

The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology (1998) 4.13

Host-reactive CD8+ memory stem cells in graft-versus-host disease. Nat Med (2005) 4.10

A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling. Proc Natl Acad Sci U S A (2000) 3.69

Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines. J Exp Med (2004) 3.43

CD8+ T cell efficacy in vaccination and disease. Nat Med (2008) 3.20

Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology (1997) 3.17

IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation. Proc Natl Acad Sci U S A (2009) 3.07

Cytokines and transcription factors that regulate T helper cell differentiation: new players and new insights. J Clin Immunol (2003) 2.93

[The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)]. Zentralbl Bakteriol B (1978) 2.92

Antiviral innate immunity pathways. Cell Res (2006) 2.80

Generation of CD8 T cell memory is regulated by IL-12. J Immunol (2007) 2.69

A constitutively expressed vaccinia gene encodes a 42-kDa glycoprotein related to complement control factors that forms part of the extracellular virus envelope. Virology (1992) 2.67

Vaccinia virus protein A46R targets multiple Toll-like-interleukin-1 receptor adaptors and contributes to virulence. J Exp Med (2005) 2.66

The biology of IL-12: coordinating innate and adaptive immune responses. Cytokine Growth Factor Rev (2003) 2.62

Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J Gen Virol (1998) 2.55

Direct priming of antiviral CD8+ T cells in the peripheral interfollicular region of lymph nodes. Nat Immunol (2008) 2.52

Innate immunity against vaccinia virus is mediated by TLR2 and requires TLR-independent production of IFN-beta. Blood (2006) 2.35

Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome. PLoS Pathog (2009) 2.24

Prime-boost vectored malaria vaccines: progress and prospects. Hum Vaccin (2010) 2.12

Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine. J Virol (2000) 2.12

Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J Gen Virol (1998) 2.06

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. J Infect Dis (2008) 2.05

Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med (1993) 2.05

The envelope protein encoded by the A33R gene is required for formation of actin-containing microvilli and efficient cell-to-cell spread of vaccinia virus. J Virol (1998) 2.05

Regulation of effector and memory T-cell functions by type I interferon. Immunology (2011) 1.58

Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. Curr Drug Targets Infect Disord (2003) 1.41

Dermal infection with vaccinia virus reveals roles for virus proteins not seen using other inoculation routes. J Gen Virol (2002) 1.36

Modified vaccinia Ankara: potential as an alternative smallpox vaccine. Clin Infect Dis (2004) 1.36

Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara. J Gen Virol (2007) 1.29

Deletion of gene A41L enhances vaccinia virus immunogenicity and vaccine efficacy. J Gen Virol (2006) 1.25

Inactivation of the viral interleukin 1beta receptor improves CD8+ T-cell memory responses elicited upon immunization with modified vaccinia virus Ankara. J Gen Virol (2005) 1.24

Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA). PLoS One (2008) 1.23

Steroid hormone synthesis by vaccinia virus suppresses the inflammatory response to infection. J Exp Med (2003) 1.19

Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. PLoS One (2007) 1.17

Clinical development of Modified Vaccinia virus Ankara vaccines. Vaccine (2013) 1.06

IL-1 enhances expansion, effector function, tissue localization, and memory response of antigen-specific CD8 T cells. J Exp Med (2013) 1.03

Modified vaccinia virus Ankara triggers type I IFN production in murine conventional dendritic cells via a cGAS/STING-mediated cytosolic DNA-sensing pathway. PLoS Pathog (2014) 1.01

Improving the MVA vaccine potential by deleting the viral gene coding for the IL-18 binding protein. PLoS One (2012) 1.01

The vaccinia virus superoxide dismutase-like protein (A45R) is a virion component that is nonessential for virus replication. J Virol (2001) 1.00

Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine. Cancer Immunol Immunother (2009) 0.99

Original encounter with antigen determines antigen-presenting cell imprinting of the quality of the immune response in mice. PLoS One (2009) 0.98

Clinical development of MVA-based therapeutic cancer vaccines. Expert Rev Vaccines (2008) 0.97

Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigens. PLoS One (2012) 0.96

Clinical applications of attenuated MVA poxvirus strain. Expert Rev Vaccines (2013) 0.95

Preparation of cell cultures and vaccinia virus stocks. Curr Protoc Protein Sci (2001) 0.92

Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling Pathways. PLoS One (2013) 0.92

Concomitant type I IFN receptor-triggering of T cells and of DC is required to promote maximal modified vaccinia virus Ankara-induced T-cell expansion. Eur J Immunol (2010) 0.92

Deletion of the vaccinia virus gene A46R, encoding for an inhibitor of TLR signalling, is an effective approach to enhance the immunogenicity in mice of the HIV/AIDS vaccine candidate NYVAC-C. PLoS One (2013) 0.92

One-step simple assay to determine antigen-specific cytotoxic activities by single-color flow cytometry. Biomed Res (2011) 0.88

Deletion of specific immune-modulatory genes from modified vaccinia virus Ankara-based HIV vaccines engenders improved immunogenicity in rhesus macaques. J Virol (2012) 0.87

TroVax, a recombinant modified vaccinia Ankara virus encoding 5T4: lessons learned and future development. Hum Vaccin (2010) 0.86

IL-12 and GM-CSF in DNA/MVA immunizations against HIV-1 CRF12_BF Nef induced T-cell responses with an enhanced magnitude, breadth and quality. PLoS One (2012) 0.85

Steroid hormone synthesis by a vaccinia enzyme: a new type of virus virulence factor. EMBO J (1992) 0.85

Characterization of DNA and MVA vectors expressing Nef from HIV-1 CRF12_BF revealed high immune specificity with low cross-reactivity against subtype B. Virus Res (2009) 0.84

Effect of 3-beta-hydroxysteroid dehydrogenase gene deletion on virulence and immunogenicity of different vaccinia viruses and their recombinants. Arch Virol (1998) 0.83

Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigens. J Virol (2014) 0.83

Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles. J Virol (2014) 0.82

MVA-85A, a novel candidate booster vaccine for the prevention of tuberculosis in children and adults. Curr Opin Mol Ther (2010) 0.82

Poxvirus vectors. Vaccine (2013) 0.80

Interleukin-1- and type I interferon-dependent enhanced immunogenicity of an NYVAC-HIV-1 Env-Gag-Pol-Nef vaccine vector with dual deletions of type I and type II interferon-binding proteins. J Virol (2015) 0.79

Recombinant modified vaccinia virus Ankara generating excess early double-stranded RNA transiently activates protein kinase R and triggers enhanced innate immune responses. J Virol (2014) 0.78

Novel mucosal DNA-MVA HIV vaccination in which DNA-IL-12 plus cholera toxin B subunit (CTB) cooperates to enhance cellular systemic and mucosal genital tract immunity. PLoS One (2014) 0.78

Deletion of Fifteen Open Reading Frames from Modified Vaccinia Virus Ankara Fails to Improve Immunogenicity. PLoS One (2015) 0.77

Truncation of gene F5L partially masks rescue of vaccinia virus strain MVA growth on mammalian cells by restricting plaque size. J Gen Virol (2013) 0.76